alexa GRP52 Is A New Sensitive Markers For Detecting Metastatic Prostatic Carcinoma | 100436
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

GRP52 is a new sensitive markers for detecting metastatic prostatic carcinoma

Joint Event on 15th International Congress on American Pathology and Oncology Research & International Conference on Microbial Genetics and Molecular Microbiology

Shaolei Lu

Warren Alpert Medical School of Brown University, USA

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681-C5-057

Abstract
Metastatic prostate cancer is frequently presented as cancer of unknown origin. To confirm the prostatic origin, prostatespecific antigen (PSA), prostein, HoxB13, and NKX3.1 are frequently used. However, these markers are regulated by androgen receptor (AR) and their expression could be suppressed by hormonal therapy or altered by chemoradiation. Based on data mining of publicly available protein expression database and AR response gene database, we identified a new marker, GRP52, and compared it to the above markers in a series of metastatic prostate cancer. We collected 46 metastatic prostate tumors, including 16 bone metastases (10 treated by hormonal ablation or chemoradiation and 6 untreated) and 30 non-bone metastases (27 treated vs 3 untreated). Immunostains of all the markers were performed and positive expression is defined as more than 5% of tumor cells with unequivocal staining in the appropriate pattern. In 27 cases of treated non-bone metastasis, the positivity rates for GPR52, NKX3.1, HoxB13, and Prostein are 100%, 87.5%, 83%, and 67%, respectively. Out of 3 cases of untreated non-bone metastasis, GRP52 missed 1 and prostein missed 2, while NKX3.1 and HoxB13 detected all of them. For 9 cases that are negative for prostein, GPR52, NKX3.1, and HoxB13 could be detected in 4, 8,7, and 6 cases respectively. All 5 markers were detected in all 16 bone metastases, except that HoxB13 could not be detected in 2 of 10 cases of treated bone metastasis. Combination of multiple markers can increase the detection sensitivity for treated metastatic prostate cancer. Decalcification has less impact on the detection of major prostatic cancer marker.
Biography

Shaolei Lu has completed his PhD at the University of Massachusetts Amherst and his MD from Shanghai Medical College of Fudan University. He is currently a surgical pathologist at Brown University. He has published more than 35 peer-reviewed papers in reputed journals.

E-mail: [email protected]

 

Top